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A B S T R A C T
Background
Oxygen (O ) is widely used in people with acute myocardial infarction (AMI) although it has been suggested it may do more harm
than good. Previous systematic reviews have concluded that there was insufﬁcient evidence to know whether oxygen reduced, increased
or had no effect on heart ischaemia or infarct size, as did our original Cochrane review on this topic in 2010. The wide dissemination
of the lack of evidence to support this widely-used intervention since 2010 may stimulate the needed trials of oxygen therapy, and it is
therefore important that this review is updated regularly.
Objectives
To review the evidence from randomised controlled trials to establish whether routine use of inhaled oxygen in acute myocardial
infarction (AMI) improves patient-centred outcomes, in particular pain and death.
Search methods
The following bibliographic databases were searched last in July 2012: the Cochrane Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library), MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO) and Web of Science (ISI). LILACS (Latin
American and Caribbean Health Sciences Literature) and PASCAL were last searched in May 2013. We also contacted experts to
identify any studies. We applied no language restrictions.
Selection criteria
Randomised controlled trials of people with suspected or proven AMI (ST-segment elevation myocardial infarction (STEMI) or non-
STEMI), less than 24 hours after onset, in which the intervention was inhaled oxygen (at normal pressure) compared to air and
regardless of cotherapies provided these were the same in both arms of the trial.
Data collection and analysis
Two authors independently reviewed the titles and abstracts of identiﬁed studies to see if they met the inclusion criteria, and indepen-
dently undertook the data extraction. The quality of studies and the risk of bias were assessed according to guidance in the Cochrane
Handbook. The primary outcomes were death, pain and complications. The measure of effect used was the risk ratio (RR) with a 95%
conﬁdence interval (CI).
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Main results
The updated search identiﬁed one new trial. In total, four trials involving 430 participants were included and 17 deaths occurred. The
pooled RR of death was 2.05 (95% CI 0.75 to 5.58) in an intention-to-treat analysis and 2.11 (95% CI 0.78 to 5.68) in participants
with conﬁrmed AMI. While suggestive of harm, the small number of deaths recorded means that this could be a chance occurrence.
Pain was measured by analgesic use. The pooled RR for the use of analgesics was 0.97 (95% CI 0.78 to 1.20).
Authors’ conclusions
There is no conclusive evidence from randomised controlled trials to support the routine use of inhaled oxygen in people with AMI. A
deﬁnitive randomised controlled trial is urgently required, given the mismatch between trial evidence suggestive of possible harm from
routine oxygen use and recommendations for its use in clinical practice guidelines.
P L A I N L A N G U A G E S U M M A R Y
Routine use of oxygen in people who have had a heart attack
Many people who are having a heart attack are routinely given oxygen to breathe. We looked for the evidence to support this practice
by searching for randomised controlled trials that compared the outcomes for people given oxygen to the outcomes for those given
normal air to breathe. We were primarily interested in seeing whether there was a difference in the number of people who died, but we
also looked at whether administering oxygen reduced pain.
We found four randomised controlled trials that compared one group given oxygen to another group given air. These trials involved
a total of 430 participants of whom 17 died. In that group, more than twice as many people known to have been given oxygen died
compared to those known to have been given air. However, because the trials had few participants and few deaths, this result does
not necessarily mean that giving oxygen increases the risk of death. The difference in numbers may have occurred simply by chance.
Nonetheless, since the evidence suggests that oxygen may in fact be harmful, we think it is important to evaluate this widely-used
treatment in a large trial as soon as possible, to make sure that current practice is not causing harm to people who have had a heart
attack.
B A C K G R O U N D
Description of the condition
Coronary heart disease (CHD) is an important cause of death
worldwide. Over seven million people every year die from CHD,
accounting for 12.8% of all deaths (WHO 2011). In the United
Kingdom (UK) and the United States (US) it is the leading cause
of death, accounting for about one-third of all deaths in people
aged 35 years or over (BHF 2007; Thom 1998).Mortality rates for
cardiovascular disease and CHD in men and women have fallen
in most developed countries. For example, comparing the 1982
to 1992 cohort to the 1971 to 1982 cohort in the US the rate was
31% lower for mortality from cardiovascular disease, 21% lower
for incidence of CHDand 28% lower for 28-day case fatality (after
adjustment for age, sex and race) (Ergin 2004). The report com-
missioned by the UK Department of Health estimated a reduc-
tion in the case fatality rate for acute myocardial infarction (AMI)
at 29 days, from 19.1% to 16.4% (Mason 2005). This reduction
was associated with both a decline in the incidence of CHD and
a reduction in the case fatality rate. Approximately 45% of the
reduction in CHD mortality is attributable to improvement in
medical therapies for coronary disease (Capewell 2000).
A commonmanifestation of CHD, often the ﬁrst, is acutemyocar-
dial infarction (AMI). The Third Global MI Task Force (Thygesen
2012) deﬁnes AMI as “any evidence of myocardial necrosis in a
clinical setting consistent with acute myocardial ischaemia.”
Myocardial ischaemia is usually the result of spontaneous compli-
cations of atherosclerosis (plaque rupture,ulceration, ﬁssuring, ero-
sion, or dissection) resulting in coronary thrombosis (type 1 AMI).
Other categories of AMI include: those produced by underlying
CHDwith an ischaemic imbalance attributable to a wide range of
factors including endothelial dysfunction, coronary spasm, coro-
nary embolism, tachy-/brady-arrhythmias, hypo- and hyperten-
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sion (type 2 AMI); sudden cardiac death induced by myocardial
ischaemia (type 3 AMI); and AMI occurring in the context of
invasive coronary procedures such as percutaneous coronary in-
tervention (PCI), in-stent thrombosis, or coronary artery bypass
grafting (CABG), categorised as subtypes 4a, 4b and 5 of AMI. By
far the most common types of AMI are types 1 and 2, to such an
extent that their incidence may be used as proxy variables to esti-
mate the prevalence of CHD in the general population. Hereafter
we will use the term ’AMI’ to refer the type 1 and type 2 AMI.
Myocardial injury may be detected through: 1. Highly sensitive
biochemical markers such as Troponin (I or T), or theMB fraction
of the creatine kinase (CKMB); 2. Electrocardiographic changes;
or 3. Imaging techniques such as echocardiography, magnetic res-
onance imaging (MRI) or radionuclide imaging (RI). To make
the diagnosis of AMI (in a clinical context) the necessary condi-
tions include a change (rise and/or fall) in cardiac biomarker val-
ues, together with at least one of the following criteria: ischaemic
symptoms; typical electrocardiographic changes; or abnormalities
in the structure or wall motion of the heart identiﬁed by imaging
techniques.
Moreover, the recognition that acute coronary syndromes repre-
sent a spectrum of pathophysiological processes rather than a uni-
form type of ’heart attack’ has led to publication of separate guide-
lines for AMI presenting with persistent ST-segment elevation
(STEMI) and non-STEMI presentations, reﬂecting the different
therapeutic options.
The in-hospital mortality rate of unselected STEMI patients ac-
cording to the Euro Heart Survey published by the European So-
ciety of Cardiology varies between 6% and 14% (Mandelzweig
2006). The most serious complications of AMI are cardiogenic
shock, heart failure, ventricular ﬁbrillation and recurrent is-
chaemia. Around 8% of people with AMI develop cardiogenic
shock (Babaev 2005), but this remains present in 29% of those
people on admission to hospital. The Global Registry of Acute
Coronary Events (GRACE) reported that heart failure occurred
in 15.6% of people with STEMI and 15.7% of those with non-
STEMI, but heart failure was present in only 13% of these patients
on admission to hospital (Steg 2004). Ventricular ﬁbrillation oc-
curred in 1.9% of people with AMI (Goldberg 2008), and recur-
rent ischaemia in 21% of those with acute coronary syndromes
(Yan 2010), of which about half presented in the ﬁrst 24 hours.
Other possible complications of AMI include pericarditis, mitral
insufﬁciency, arrhythmias and conduction disturbances.
The cornerstone of contemporary management of people with
STEMI is reperfusion therapy, with either primary percutaneous
coronary intervention (PCI) or thrombolytic treatment. If less
than 12 hours has elapsed from the onset of symptoms, recom-
mended treatments in international guidelines include morphine,
oxygen (O ), nitrates and aspirin (MONA) (O’Connor 2010;
O´ Gara 2013; StegG2012). Some of these treatments have awell-
established research base, while others do not (Nikolaou 2012;
O’Driscoll 2008; SIGN 2010).
Description of the intervention
Inhaled oxygen at normal pressure delivered by face mask or nasal
cannula, at any concentration.
How the intervention might work
Myocardial infarction occurs when the ﬂow of oxygenated blood
in the heart is interrupted for a sustained period of time. The ra-
tionale for providing supplemental oxygen to a person with AMI
is that it may improve the oxygenation of the ischaemic myocar-
dial tissue and reduce ischaemic symptoms (pain), infarct size and
consequent morbidity and mortality. This pathophysiological rea-
soning has face validity.
Why it is important to do this review
Although it is biologically plausible that oxygen is helpful, it is also
biologically plausible that it may be harmful. Potentially harm-
ful mechanisms include the paradoxical effect of oxygen in reduc-
ing coronary artery blood ﬂow and increasing coronary vascular
resistance, measured by intracoronary Doppler ultrasonography
(McNulty 2005; McNulty 2007); reduced stroke volume and car-
diac output (Milone 1999); other adverse haemodynamic conse-
quences, such as increased vascular resistance from hyperoxia; and
reperfusion injury from increased oxygen free radicals (Rousseau
2005).
A systematic review of human studies that included non-ran-
domised studies did not conﬁrm that oxygen administration di-
minishes acute myocardial ischaemia (Nicholson 2004). Indeed,
some evidence suggested that oxygen may increase myocardial is-
chaemia (Nicholson 2004). Another recent narrative review of
oxygen therapy (Beasley 2007) also sounded a cautionary note. It
referenced a randomised controlled trial (RCT) conducted in 1976
(Rawles 1976) showing that the risk ratio of death was 2.89 (95%
conﬁdence interval (CI) 0.81 to 10.27) in participants receiving
oxygen compared to those breathing air. While this suggested that
oxygen may be harmful, the increased risk of death could easily
have been a chance ﬁnding. A recent review (Wijesinghe 2009)
looked at the effect of oxygen on infarct size in people with AMI
and concluded that “There is little evidence by which to determine
the efﬁcacy and safety of high ﬂow oxygen therapy in MI. The
evidence that does exist suggests that the routine use of high ﬂow
oxygen in uncomplicated MI may result in a greater infarct size
and possibly increase the risk of mortality”.
Despite this lack of robust evidence of effectiveness prior to the
publication of our 2010 Cochrane review of the evidence, oxygen
administration was widely recommended in international guide-
lines (AARC 2002; AHA 2005; Anderson 2007; Antman 2002;
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ILCOR 2005; Van de Werf 2008). Some guidelines were more
cautious; for example, the EuropeanGuideline (Bassand 2007) did
not recommend routine oxygen use in acute coronary syndrome
(ACS) and the Scottish Intercollegiate Guidelines Network guid-
ance (SIGN 2007) only recommended oxygen use in hypoxaemia
(< 90% saturation), noting that there was no clinical evidence for
its effectiveness and referring to animal models that showed a re-
duction in infarct size.
Guidelines published since the 2010 Cochrane review have tended
tomove to a more cautious position reﬂecting the lack of evidence.
In 2010, for example, the American Heart Association Guidelines
for Cardiopulmonary Resuscitation and Emergency Cardiovascu-
lar care stated that:
“EMS providers administer oxygen during the initial assessment
of patients with suspected ACS. However, there is insufﬁcient
evidence to support its routine use in uncomplicated ACS. If the
patient is dyspnoeic, hypoxaemic, or has obvious signs of heart
failure, providers should titrate therapy, based on monitoring of
oxyhaemoglobin saturation, to 94%. (Class I, LOE)“ (O’Connor
2010).
An updated SIGN guidance states:
“A Cochrane review found no conclusive evidence from ran-
domised controlled trials to support the routine use of inhaled
oxygen in patients with acute MI. There is no evidence that rou-
tine administration of oxygen to all patients with the broad spec-
trum of acute coronary syndromes improves clinical outcome or
reduces infarction size” (SIGN 2010).
In 2011 an Addendum to the National Heart Foundation of Aus-
tralia/Cardiac Society of Australia and New Zealand Guidelines
for the Management of Acute Coronary Syndromes (ACS) was
published and stated that:
“There is currently insufﬁcient evidence to formulate clear rec-
ommendations about oxygen therapy [52]. Deﬁnitive trials are
needed to answer this question” (Chew 2011).
Similarly the 2012 ESC guidelines for STEMI, citing the
Cochrane review, now state:
“Oxygen (by mask or nasal prongs) should be administered
to those who are breathless, hypoxic, or who have heart fail-
ure.Whether oxygen should be systematically administered to pa-
tients without heart failure or dyspnoea is at best uncertain. Non-
invasive. monitoring of blood oxygen saturation greatly helps
when deciding on the need to administer oxygen or ventilatory
support” (Steg G 2012).
The 2013 ACCF/AHA Guideline for the Management of ST-
ElevationMyocardial Infarctionhave a similar change in emphasis:
“Few data exist to support or refute the value of the routine use
of oxygen in the acute phase of STEMI, and more research is
needed. A pooled Cochrane analysis of 3 trials showed a 3-fold
higher risk of death for patients with conﬁrmed acute MI treated
with oxygen than for patients with acuteMImanaged on room air.
Oxygen therapy is appropriate for patients who are hypoxaemic
(oxygen saturation <90%) and may have a salutary placebo effect
in others. Supplementary oxygen may, however, increase coronary
vascular resistance. Oxygen should be administered with caution
to patients with chronic obstructive pulmonary disease and carbon
dioxide retention”. (O´ Gara 2013).
The British Heart Foundation (BHF), in response to the doubts
about oxygen use raised by Beasley 2007, originally stated in an
article in The Guardian 2007 that “The current practice of giving
high-ﬂow oxygen is an important part of heart attack treatment.
Best practice methods have been developed and reﬁned over the
years to ensure the best possible outcome for patients. There is
not enough evidence to change the current use of oxygen therapy
in heart attacks”. Almost three years after the publication of the
ﬁrst Cochrane Review the use of oxygen in AMI and more in
general in the coronary acute syndromes is still controversial (
Shuvy 2013). We think that, given the evidence cited, it would
have beenmore appropriate to conclude that despite decades of use
there is inadequate clinical trial evidence to unequivocally support
routine administration of oxygen. The BHF subsequently stated
that the 2010 Cochrane review (BHF 2010) “highlights the need
for more research into the effects of oxygen when it is given during
a heart attack. Until recently, heart attack patients were routinely
treated with oxygen but we simply do not have enough evidence
to know if that treatment is beneﬁcial or harmful.”
With the lack of collective certainty about the use of oxygen, it is
time that this treatment is re-assessed. In general, practice should
not be based on tradition but on proven beneﬁt and safety. Given
that the 1976 trial (Rawles 1976) was suggestive of potential harm
from oxygen in suspected AMI, it is important that the evidence
base for the current guidance recommending the use of oxygen
be systematically reviewed and, if necessary, further research be
undertaken to clarify whether this intervention does more harm
than good. If the only robust evidence is suggestive of potentially
serious harm, even if the result is not statistically signiﬁcant, it
reinforces our opinion that this intervention should not be rou-
tinely used, however sound the underpinning pathophysiological
reasoning.
O B J E C T I V E S
To determine if routinely giving oxygen (O ) to people with sus-
pected and proven acute myocardial infarction (AMI) (ST-seg-
ment elevation (STEMI) and non-STEMI) does more good than
harm by reviewing the evidence from randomised controlled trials
using patient-centred outcomes, in particular death and pain.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials (RCTs), in any language, with any
length of follow-up, and any publication status (full publication,
abstract only or unpublished).
Types of participants
Adults of any age treated, in a pre-hospital or a hospital setting,
for suspected or proven AMI (STEMI or non-STEMI), within
less than 24 hours after onset of symptoms, regardless of any co-
therapy (for example a reperfusion therapy) provided this is the
same in both arms of the trial.
Types of interventions
The intervention is routinely-given inhaled oxygen administered
by any device at normal pressure for one hour or more within the
ﬁrst 24 hours after the onset of symptoms of AMI. The compara-
tors are air, or air with titrated oxygen in the event of desaturation.
Excluded interventions are hyperbaric oxygen or aqueous oxygen
therapy (unless the studies include arms with air or oxygen at
normal pressure).
Types of outcome measures
We sought only clinically relevant outcomes. The primary out-
come for the systematic review was prespeciﬁed as mortality; the
secondary outcomes were pain and any other complications (such
as heart failure, pericarditis and rhythm disorders). Other indirect
clinical outcomes such as infarct size estimated through different
methods (electrocardiogram (ECG), cardiac enzymes, Troponin
T, Brain Natriuretic Peptide (BNP), or magnetic resonance imag-
ing (MRI)) were also employed.
Surrogate outcomes, such as reperfusion arrhythmias and arterial
oxygen saturation, were not included as these may not necessarily
correlate well with clinically important outcomes.
Search methods for identification of studies
Electronic searches
We searched the following bibliographic databases (from start of
database to 17 July 2012):
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library);
• MEDLINE (Ovid);
• MEDLINE In-Process (Ovid);
• EMBASE (Ovid);
• CINAHL (EBSCO);
• Web of Science (ISI).
We also searched LILACS (Latin American and Caribbean Health
Sciences Literature) and the PASCAL database in May 2013. ZE-
TOC was last searched in February 2010.
A RCT search ﬁlter as recommended in the Cochrane Handbook
for Reviews of Systematic Interventions (Cochrane Handbook) has
been applied to the 2012 searches of MEDLINE and EMBASE
and adaptations of these to CINAHL and Web of Science.
We searched the following databases for ongoing trials:
• Current Controlled Trials metaRegister http://
www.controlled-trials.com/mrct/;
• International Clinical Trials Registry Platform (ICTRP),
World Health Organization. http://www.who.int/ictrp/network/
en/
Details of the database search strategies are in Appendix 1 (for
2010) and Appendix 2 (for 2012).
Searching other resources
We searched proceedings of annual meetings and conferences of
professional bodies (American Heart Association, British Cardio-
vascular Society, European Society of Cardiology and American
College of Cardiology) for relevant abstracts.
We contacted experts in the ﬁeld to locate any unpublished studies,
and checked citations from key references.
No date or language restrictions were applied to the searches.
Data collection and analysis
We used the standard methods of The Cochrane Collaboration as
described in the Cochrane Handbook so that the review methods
are consistent with current recommendations. We used Review
Manager 5 (RevMan) for the analysis.
Selection of studies
Two authors independently reviewed the titles and abstracts of
studies identiﬁed in the searches to see if they met the above inclu-
sion criteria. We obtained study reports in full text when inclusion
could not be decided from the title or abstract.
Data extraction and management
Two authors independently evaluated the methodological quality
and undertook independent data extraction using an agreed data
extraction form. We resolved differences by discussion. The data
were entered into Review Manager 5 by one review author and
checked by two others.
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Assessment of risk of bias in included studies
Risk of bias in individual studies
Weused the two-part tool described in Section8.5 of theCochrane
Handbook. We explored the six speciﬁc domains of: sequence
generation; allocation concealment; blinding (participants, per-
sonnel and outcome assessors); incomplete outcome data; selective
outcome reporting; and other potential threats to validity.
For each trial, two review authors independently ﬁrst described
the design characteristics relating to each domain and then judged
the risk of bias associated with the main outcome. A nominal scale
was used for the judgement: low, high or unclear risk of bias.
Risk of bias across studies
We did an overall assessment of risk of bias for every outcome
within the review for each domain and using a similar scale: low
risk of bias in all domains, unclear risk of bias for one or more
domains, and high risk of bias for one or more domains.
When meta-analysis was undertaken we summarised the risk of
bias for the main outcomes, across studies. We resolved disagree-
ments between review authors in the description or in the judge-
ment by consensus without the need for recourse to a third review
author.
Measures of treatment effect
We looked at the risk ratio (RR) of death and report this in pref-
erence to risk difference. This was because the trials were old (the
main trial was undertaken in the era before thrombolysis was rou-
tine) and we anticipated that there would be higher control event
rates than would be expected today. We also looked for differences
in mean pain scores. These were not given, and we therefore used
the risk ratio of opiate use as a proxy for pain. We used the differ-
ences in mean for continuous measurement of infarct size such as
cardiac enzymes, Troponin T, BNP or MRI.
Unit of analysis issues
In the main trial (Rawles 1976), 200 participants with AMI were
randomised but the results were only analysed for the 157 who
were later conﬁrmed to have had an AMI. Similarly in the most
recent trial (Ranchord 2012) the ﬁve participants in which AMI
was not conﬁrmed and another seven withdrawn participants were
excluded from the analysis. It is legitimately open to debate as to
whether people who did not have an AMI should be included in
a study of the beneﬁts of oxygen in AMI. Theoretically diagnosis
may be more certain today, but not at the beginning of symptoms.
On the other hand, we treat suspected MIs and these represent
some of the people to whom a treatment would be given. We have
therefore performed two analyses: one in participants who had
conﬁrmed MI in Rawles 1976 and Ranchord 2012, and a second
that also covered all participants from the other two trials in a strict
intention-to-treat (ITT) analysis that included the 43 participants
from the Rawles trial who did not have an AMI conﬁrmed and the
12 withdrawn participants from the Ranchord study. This was to
preserve the strict randomisationprocess and tominimise selection
bias.
Dealing with missing data
We conducted an ITT analysis whenever possible. We contacted
study authors for missing data.
Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the outcomes
tables and using the I² statistic (where an I² < 60% was considered
to demonstrate moderate heterogeneity) (Higgins 2003).
Assessment of reporting biases
As there were only four studies that met the inclusion criteria, it
was not possible to explore reporting bias using funnel plots or the
Begg (Begg 1994) and Egger ( Egger 1997) tests.
Data synthesis
We undertook meta-analyses where data were available and it was
clinically sensible to do so, using both ﬁxed-effect and random-
effects models. We reported the results using both models because
we recognise that readers may have different perspectives (for ex-
ample priors, values or contexts) and different people may wish to
see the results with the different mathematical assumptions.
Subgroup analysis and investigation of heterogeneity
The data were too sparse to permit adequate exploration of all the
subgroups that had been prespeciﬁed for analysis (such as timing
and duration of oxygen therapy; pre-existing levels of hypoxaemia;
other measures of severity of infarction).We undertook an analysis
including only the trials undertaken during the reperfusion era, as
these reﬂect today’s clinical practice.
Sensitivity analysis
Similarly, our intention to explore the effect of trial quality in a
sensitivity analysis was limited by the number of trials and the
quality of reporting. We undertook separate analyses using the
conﬁrmed AMI population and the ITT population, and under-
took a ’best-case’ scenario, ’worst-case’ scenario sensitivity analysis
for the missing data on deaths (Wilson 1997).
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R E S U L T S
Description of studies
Results of the search
We identiﬁed 115 new articles with the updated search in July
2012. The removal of duplicates left 77 new articles for screen-
ing. One new randomised controlled trial (RCT) was eligible for
inclusion (Ranchord 2012).
Including the papers identiﬁed in the previous version of the re-
view, we retrieved a total of 2646 articles and screened 2305 (after
the removal of duplicates) (Figure 1). Based on title and abstract,
2157 were excluded and 148 full papers retrieved. A further 125
were not RCTs or were RCTs not related to our review. Of the
remaining 23 papers, 16 were excluded for various reasons and
two are references for an ongoing study. This leaves ﬁve papers re-
porting four trials that met the inclusion criteria (Ranchord 2012;
Rawles 1976; Ukholkina 2005; Wilson 1997). The process with
reasons for exclusions is described in Figure 1 and the list of the ex-
cluded trials given in the table Characteristics of excluded studies.
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Figure 1. Study flow diagram.
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We identiﬁed in the trials registers three ongoing trials (July 2012),
two of which have begun recruitment.(Characteristics of ongoing
studies). All three are parallel designs to compare oxygen (O )
versus air (or titrated oxygen) in people with suspected acute my-
ocardial infarction (AMI). In two studies the primary outcome
is infarct size estimated by echocardiography, magnetic resonance
imaging (MRI) or biochemical markers; in the third one the main
outcome is in-hospital mortality (this study, despite having been
registered in 2009, has yet to begin recruitment).
Included studies
The four included trials were reported between 1976 and 2012
(Ranchord 2012; Rawles 1976; Ukholkina 2005; Wilson 1997).
Two were conducted in the UK (Rawles 1976; Wilson 1997) one
in Russia (Ukholkina 2005) and one in New Zealand (Ranchord
2012). All four studieswere parallel-design, randomised controlled
trials. One was double-blind (Rawles 1976) and the other three
were open-label.
Population: a total of 535 participants were recruited, of whom
73.2% were men. Participants with suspected AMI were recruited
in two studies (Ranchord 2012; Rawles 1976) and only people
with conﬁrmed AMI in the other two. The mean ages in years
(and standard errors where given) of the included participants in
each group were as follows: Rawles 1976: air 50.8 (2.4), O 51.3
(1.7); Wilson 1997: air 64, O 65; Ukholkina 2005: air 53.5
(1.06), O 55.6 (1.33); Ranchord 2012: air 60 (12.8), O 62.1
(12.5).
Intervention: in all four included trials the intervention was in-
haled oxygen at 4 to 6 L/min. This was given by mask in three
studies and by a nasal cannula in the other study. The comparator
was air in three studies, breathed normally in the two open-label
studies and given at 4 to 6 L/min by facial mask in the double-
blind study. In the remaining study the comparison was titrated
oxygen delivered by nasal prongs or mask adjusting the ﬂow-rate
to achieve an oxygen saturation of 93% - 96%.
Outcomes: death was reported in all four studies. Pain or analgesic
use (as a proxy for pain) was reported in two studies. Two stud-
ies included infarct size estimated by electrocardiogram (ECG),
biochemical markers (creatine kinase (CK),T troponin, BNP) or
MRI as an indirect clinical outcome.
The main characteristics of the included studies are in the table
Characteristics of included studies.
Excluded studies
Of the 125 excluded articles, 71 did not report original data; 37
were not RCTs; 17 were RCTs of interventions which were not
relevant to our study; and 16 papers reported studies which had
a different oxygen intervention (eight used hyperbaric oxygen, six
aqueous oxygen, one oxygen associated with haemoglobin, and
one oxygen combined with nitric oxide versus placebo for pain
control). The two remaining papers were the protocol and the pilot
of an ongoing trial (NCT01272713). The main characteristics of
the excluded studies are in the table Characteristics of excluded
studies.
Risk of bias in included studies
Randomisation
There was no description of how the sequence for allocation was
generated in three studies (Rawles 1976; Ukholkina 2005;Wilson
1997). In Ranchord 2012 a random number sequence was gen-
erated by a computer programme. This study was undertaken in
two centres and randomisation was not stratiﬁed by centre.
Allocation concealment
In three studies allocation was concealed using numbered sealed
envelopes (Ranchord 2012; Rawles 1976; Wilson 1997). The
method of allocation concealment was not reported in Ukholkina
2005. In Ranchord 2012 (two centres) there is no description of
how the envelopes were distributed to each centre.
Blinding
Only Rawles 1976 was blinded. This was done by using shrouded
cylinders but there is no information about how effective this was.
Nursing staff were not aware that the record of opiate administra-
tion would be used as a proxy measure of pain. We think that the
use of shrouded cylinders left blinding potentially compromised
and that therefore the possibility of performance and observer bias
cannot be excluded. However, while this could affect the assess-
ment of the surrogate outcomes for pain, it is much less likely to
have affected the primary outcome of this review, which was death
(Wood 2008). We have no clear information whether infarct size
measurement (through ECG, enzymes or BNP) was done blind
(thoughwe presume that it was). Finally inRanchord 2012 the car-
diologist who measured the infarct size through MRI was blinded
to treatment received by the participant and to biomarkers data.
Performance and observer biases were possible in the three un-
blinded studies, which may have affected the evaluation of the
surrogate outcome for pain inWilson 1997 (this outcome was not
reported in the Ukholkina and Ranchord trials). The assessment
of the primary outcome (death) and the other secondary outcome
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of complications such as recurrent ischaemia or AMI, heart fail-
ure, arrhythmias and pericarditis were less likely to be subject to
signiﬁcant observer bias. On the other hand the methods used
for infarct size estimation (ECG, creatine kinase, Troponin T, or
MRI) are quite robust to observer bias, so these measures may be
considered free of observer bias.
Incomplete outcome data addressed
All participants were followed to discharge inRawles 1976 but ran-
domisation was undertaken before the diagnosis was conﬁrmed.
AMI was not conﬁrmed in 21.5% of those with suspected AMI.
Although this may appear high, it is not inconsistent with diag-
nostic techniques in the 1970s. Of the 105 people randomised
to oxygen and the 95 to air, AMI was not conﬁrmed in 25 and
18 participants respectively. The characteristics of those in whom
AMI was not conﬁrmed were similar in both groups and there
were no deaths among the excluded individuals.
In Wilson 1997 , it was unclear for how long participants were
followed up. Eight people were excluded from the analysis: one
death, one stroke, four who withdrew consent and two because
data were incomplete. This is 16% of the participants and the
expected effect on the results for the primary event was very low;
the risk of bias was therefore high, but its direction is unknown.
In Ukholkina 2005 the outcomes were measured for 10 days and
no participants were lost to follow-up. However, no explicit data
were provided about the participants who were excluded post-
randomisation because of failed revascularisation or the relative
number of failed revascularisations in each group. The mismatch
between the numbers reported in the tables and the text suggest
that two participants may have been excluded from the air group
and four from the oxygen group, but we cannot be certain. Conse-
quently we could not include these participants in the intention-
to-treat analysis. We therefore think there is a high risk of bias for
the outcomes we measured.
In Ranchord 2012 12 participants were excluded after randomi-
sation (four in the experimental group and eight in the control
group). The outcomes of these participants were not reported and
they were excluded from the analysis in the published study re-
port. The reasons for withdrawal were: in ﬁve cases the absence
of formal consent; in ﬁve cases a wrong diagnosis of STEMI (two
cases of acute pericarditis and three cases with normal coronary
arteries); and two people had cardiogenic shock which was an ex-
clusion criterion for the study. The group to which these partici-
pants had been allocated was not reported.
We contacted authors to try and ﬁnd out to which groups the
12 withdrawn participants had been allocated and their vital sta-
tus, so that we could include them in an intention-to-treat (ITT)
analysis. Although the authors replied, the information provided
was contradictory and of limited value. Initially we were told that
ﬁve people had been withdrawn because they did not consent and
that the other seven had not been randomised. When we enquired
further about this because it contradicted the published report, we
were told that these seven had been randomised. Of concern to
us was the fact that the distribution of their allocation to groups
subsequently provided was not consistent with the numbers in the
published trial report. The authors declined to provide the mor-
tality outcomes for the participants who had alternative diagnoses,
stating that “Although they are described as ‘randomised and with-
drawn’ in the manuscript, they received no study treatment. For
these reasons we are ﬁrmly of the view that these subjects should
not be included in the mortality analysis.” This failure to appreci-
ate the nature of ITT analysis compounded our concerns raised by
the inconsistencies in the allocation information. The authors felt
unable to tell us the mortality status of the ﬁve participants who
did not consent on the grounds that “if they have not consented
then we can collect no further details about them”. While we un-
derstand that trial-speciﬁc data could not be collected on these
people,mortality can be known by public methods, and we believe
therefore that providing us with this information would not have
been an ethical breach. However we appreciate that others may
judge this differently. The only information of use was that the
three participants withdrawn because they had normal coronary
arteries, were alive at the end of the study period.
The two cases excluded from the analysis by cardiogenic shock
merit special comment. While cardiogenic shock was an exclusion
criterion of the study, it is important to recognise that this is a dy-
namic clinical condition which is present on admission to hospital
only in 29% of those who go on to develop this complication. It
is not reported in the paper whether the participants had cardio-
genic shock when they arrived at the hospital or not. If cardio-
genic shock developed after randomisation but before treatment,
then the exclusion of these participants could bias the results since
people with cardiogenic shock have a higher mortality rate. This
illustrates the importance of ITT analysis.
As we were unable to include these participants in the ITT analysis
because mortality data were withheld, we undertook a sensitivity
analysis with a ’worst-case’ scenario in which we tested the robust-
ness of the current estimate by assuming that both participants
received oxygen but died.
Selective outcome reporting
No study protocols were available. Rawles 1976 was the best-
quality study and we believe that the report probably included all
the prespeciﬁed variables. In Wilson 1997 the primary purpose
was to look at the incidence and degree of hypoxaemia and the
effect of oxygen on hypoxaemia, rather than this review’s primary
outcome of death; the participant who died was excluded from
the analysis. Despite contacting the authors, we were unable to
establish in which group the death occurred and this study could
not be included in the meta-analysis. We carried out a sensitivity
analysis to assess the potential risk of bias.
In Ukholkina 2005, ECGs were mapped to estimate the surrogate
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outcome of infarct size but only in a subset of 31 participants in
the oxygen group; there was no information for the air group. We
therefore believe that meaningful conclusions cannot be drawn
about infarct size. We do not think the pain and death outcomes
were subject to selective reporting.
In Ranchord 2012 the infarct size, estimated by MRI, was under-
taken only in a small subgroup of 71 participants (Selective report-
ing of subgroup). In addition neither the protocol nor the trial re-
port give any deﬁned criteria on whether or not to perform MRI,
so this analysis should be considered a non-randomised compari-
son. On the other hand, given that theMRI was performed four to
six weeks after AMI, this speciﬁc subgroup represents a cohort of
survivors, which also needs to be taken into account in the infarct
size comparison.
Baseline characteristics
Overall, the two groups appeared similar after randomisation in
Rawles 1976 andWilson 1997. InUkholkina 2005 the two groups
appeared similar in age, smoking, hypertension, unstable angina
and cholesterol. Therewas a difference (not statistically signiﬁcant)
in the Killip stage, with more Killip II in the oxygen group than
in the air group; time to revascularisation was 41 minutes shorter
in the air group (P = 0.052), which even if due to chance may
have important clinical implications for our outcomes of interest.
In Ranchord 2012 the two groups appear similar in age, sex, body
mass index, diabetes, hyperlipidaemia, hypertension and previous
coronary artery bypass grafting (CABG). There were differences
in the number of previous percutaneous coronary interventions
(PCIs), and in the infarct territory, with less anterior infarction
in the experimental group that in the control group (18% versus
31%).
Other biases
No other biases were identiﬁed in Rawles 1976 or Wilson 1997.
Ukholkina 2005 reported differences in infarct size between the
two interventions but the authors did not specify the time after
symptomonset when creatine phosphokinaseMandB isoenzymes
(MB-CPK) were measured; they were not measured at the same
time in all participants. In addition, no information was provided
about the consistency and validity of the method used to map
myocardial damage (number and blinding of observers; reliabil-
ity and repeatability of their measurements; whether there were
disagreements and, if so, how these were resolved). While these
methodological weaknesses call into question the reliability of the
estimation of myocardial damage, they do not affect themain out-
comes of this review. Only Ukholkina 2005 reported complica-
tions but there was an inconsistency between the data in the table
and the text. We recalculated complication rates and used these
data in our analysis.
In Ranchord 2012 before randomisation pre-hospital oxygen was
administered to the experimental and control groups (86.8% and
63% respectively). If the effect of oxygen is truly determinant on
the outcome, then this prerandomisation intervention could have
produced a bias in effect estimation toward the null hypothesis
(i.e. a reduction of the study power).
Summary of risk of bias
Death as an outcome had a low risk of bias in Rawles 1976, was
not reported adequately inWilson 1997 and had a high risk of bias
in Ukholkina 2005. There are also the ’withdrawn’ participants
from Ranchord 2012, for which we had no outcome data and do
not therefore know their vital status. We therefore consider the
overall risk of bias for mortality in the meta-analyses to be high.
For pain we consider the risk of bias in Rawles 1976 to be unclear
and that there is a high risk of bias in Wilson 1997. Consequently
we consider the risk of bias in themeta-analysis for pain to be high
(Figure 2; Figure 3).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Effects of interventions
Mortality
All four trials reported the observed mortality. Rawles 1976 found
more deaths in the group randomised to oxygen than in the air
group, both for all randomised participants (suspected AMI) and
for those with conﬁrmed AMI. Wilson 1997 described one death
but did not report in which group this occurred. We contacted
both of the authors of the original paper, who conﬁrmed that they
no longer had the trial data and did not remember in which arm
the death and the stroke had occurred; however, they stated that 25
participants had been randomised into each group. In Ukholkina
2005, only one person out of 58 died in the oxygen group and
none out of 79 participants in the air group. In Ranchord 2012
one participant out of 68 died in the high oxygen group and two
out 68 in the titrated group. Twelve participants (four in the high
oxygen group and eight in the titrated group) were withdrawn
after randomisation, with the mortality data for these 12 people
not reported in the paper. We contacted the authors of the trial,
but they were unable to provide the missing data for these cases.
Only the results from three of the four studies (Ranchord 2012;
Rawles 1976; Ukholkina 2005) could be combined. When the
data were pooled, twice as many people on oxygen died as in the
group given air. This suggests that oxygen may be harmful but,
because of the small numbers of people in the trials, this may sim-
ply be due to chance. The complete results are given numerically
below, and a sensitivity analysis for the missing data from Wilson
1997 and Ranchord 2012 studies are also presented.
Meta-analysis for mortality in participants with conﬁrmed AMI:
risk ratio (RR) 2.11 (95% conﬁdence interval (CI) 0.78 to 5.68;
I² = 0%, ﬁxed-effect model) (Analysis 1.1). This remained un-
changed when applying a random-effects model (Analysis 1.2).
Meta-analysis for mortality in an ITT population (including those
who did not have AMI): RR 2.05 (0.75 to 5.58; I² = 0%, ﬁxed-
effect model) (Analysis 1.3).This remained unchanged when ap-
plying a random-effects model (Analysis 1.4).
Sensitivity analysis formissing information about the arm inwhich
the death occurred in theWilson trial (ITT analysis): a ’worst-case’
scenario assuming that the participant who died was in the oxygen
arm gave a RR of death of 2.88 (95% CI 0.88 to 9.38). A ’best-
case’ scenario assuming that the participant who died was in the
air arm gave a RR of death of 2.06 (95% CI 0.67 to 6.37). In both
cases we used a ﬁxed-effect model. Sensitivity analysis for missing
information about the group in which the two participants with
cardiogenic shock were allocated: assuming that both participants
died, a ’worst-case’ scenario in which both were in the oxygen
arm gave a RR of 2.42 (95% CI 0.91 to 6.41), and a ’best-case’
assuming that the participants were in the control arm gave a RR
of 0.26 (95% CI 0.03 to 2.31).
The subgroup analysis, including only the two reperfusion era tri-
als, gave a RR of death of 1.60 (95% CI 0.21 to 6.32). Unfortu-
nately, despite being recent, these two studies did not meet current
standards of trial design and conduct and have a high risk of bias
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(see Risk of bias in included studies and Figure 3).
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Pain
Pain was not explicitly measured but the authors reported diamor-
phine use as a proxy for pain. In Rawles 1976, a similar propor-
tion of participants from both groups received analgesia. The total
dosage was similar: 54.3% of randomised participants (71.3% of
those with conﬁrmed AMI) in the oxygen group received analge-
sia, with an average of 2.1 doses (standard deviation (SD) 1.5), but
it was not clear whether the denominator was participants who
used diamorphine or all participants; 54.7% of randomised par-
ticipants (67.5% of those with conﬁrmed AMI) in the air group
received analgesia, with an average of 2.0 doses (SD 1.4), but again
the denominator population was not clearly deﬁned. In Wilson
1997 the authors reported opiate use as a proxy for pain. Although
50 people were randomised, results were only reported for 42, as
follows: 16 of 22 participants (72.7%) in the oxygen group used
opiates; 18 of 20 participants (90%) in the air group used opiates.
Ukholkina 2005 did not measure pain or analgesic use.
Thus we can only combine results from two studies. There was no
difference in analgesic use between the oxygen and the air groups.
The complete results are given numerically below.
Meta-analysis for analgesic use in conﬁrmed AMI: RR 0.99 (95%
CI 0.83 to 1.18; I² = 54%, ﬁxed-effect model) (Analysis 1.5). This
was slightly altered when
a random-effects model was applied: RR 0.94 (95% CI 0.72 to
1.23; I² = 54%) (Analysis 1.6).
Meta-analysis for analgesic use in the ITT population (including
those who did not have an AMI): RR 0.97 (95% CI 0.78 to
1.20; I² = 0%, ﬁxed-effect model) (Analysis 1.7). This remained
unchanged using a random-effects model: RR 1.01 (95% CI 0.75
to 1.34; I² = 0%) (Analysis 1.8).
Complications
Ukholkina 2005 explored complications such as heart failure, peri-
carditis and rhythm disorders. The RR of complications (exclud-
ing recurrent ischaemia) was 0.68 (95%CI 0.45 to 1.03) (Analysis
1.9).
Infarct size estimation
Three of the four studies explored the effect of oxygen on the
infarct size (Ranchord 2012; Rawles 1976; Ukholkina 2005). As
they used quite different methods to estimate the infarct size it
was not possible to synthesise the ﬁndings (qualitatively or quan-
titatively).
D I S C U S S I O N
Summary of main results
We identiﬁed four studies meeting our inclusion criteria. None
demonstrated that oxygen therapy in people with AMI does more
good thanharm, based on clinical outcomes. In both the intention-
to-treat meta-analysis and the conﬁrmed AMImeta-analysis, there
weremore deaths among those people onoxygen than among those
on air, although these results did not reach statistical signiﬁcance
and could simply be a chance occurrence. There was no clinically
or statistically signiﬁcant difference in analgesia use between the
two treatments. Finally there was no clear effect of the intervention
in reducing infarct size estimated through different methods in
subsets of patients.
Overall completeness and aplicability of
evidence
Regarding the applicability of the evidence three aspects should
be pointed out:
Firstly, the Rawles andWilson ( Rawles 1976;Wilson 1997) stud-
ies were undertaken before the reperfusion era (primary percu-
taneous coronary intervention (PPCI) or thrombolysis) and also
before the use of treatments such as beta-blockers, aspirin, an-
giotensin-converting enzyme inhibitors or modern antiplatelet
therapies, and thus their results may not be applicable in today’s
context. While the two trials in the sensitivity analysis including
only the reperfusion era trials were at high risk of bias, the result
risk ratio (RR) of death of 1.60 (95%conﬁdence interval (CI) 0.21
to 6.32) should nevertheless be taken into account when planning
further studies (for example, in calculating sample sizes).
Moreover the reported case fatality rates from AMI have fallen in
recent decades (Koopman 2012, Schmidt 2012, Smolina 2012,
Yeh 2010). In the included studies for this review, hospital mor-
tality among control participants was only 1.7%. This rate is
lower than that observed in contemporary routinely collected data
(Babaev 2005, Movahed 2009). While this may be explained by
the fact that only lower-risk participants were recruited, it could
also be due to a chance deﬁcit of deaths in the control arm, which
would have contributed to the apparent difference between the
oxygen and control groups. This aspect should be considered to
inform selection criteria of patients in future studies.
A further issue to consider when assessing the contemporary rele-
vance and applicability of the earlier studies in our review is that
the deﬁnition of AMI has changed several times in the intervening
years, reﬂecting better understanding of underlying pathophysio-
logical processes and developments in diagnostic techniques such
as the high sensitivity troponins. Furthermore, it is now recognised
that acute coronary syndromes represent a spectrum of pathophys-
iological processes rather than a uniform type of ’heart attack’.
Notably, there are now separate guidelines for STEMI and non-
STEMI presentations, reﬂecting the different therapeutic options.
Supplementary oxygen is under investigation in STEMI patients
currently, but we have not identiﬁed any trials (reported, ongoing
or in development) of oxygen in non-STEMI patients. This spec-
14Oxygen therapy for acute myocardial infarction (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
trum of ACS should be considered in further studies.
Quality of the evidence
The evidence (published and unpublished) in support of such a
widespread practice is surprisingly sparse and scattered. The qual-
ity of the included studies was generally poor and the risk of bias
was high for both our main outcomes. Two of the studies (Rawles
1976; Wilson 1997) were not recent and were carried out prior to
the improvements in trial design, conduct and reporting that have
taken place in the last decade; unfortunately the two recent studies
were not conducted or reported in full accord with these advances.
Therefore the risk of bias for death and pain across studies is high,
and with regard these outcomes the results must be interpreted
with caution. Other surrogate outcomes such as infarct size have
been measured inappropriately or in a subset of the study popu-
lation that represents a cohort of survivors of AMI.
Potential biases in the overview process
We were unable to determine if there was any publication bias
using formal methods, as we found only four studies for inclusion.
The possibility cannot be excluded that there are unpublished
or ongoing studies, especially in foreign languages, that were not
indexed in the electronic databases we searched.
Regarding heterogeneity, in the meta-analysis for analgesic used
in conﬁrmed AMI we found moderate heterogeneity (I² = 54%),
which disappeared in the intention-to-treat analysis.While the two
studies used in the meta-analysis had differences in their design
(for example, blinded versus open-label) and attrition rates (much
higher in Wilson 1997), it was not possible to investigate the
heterogeneity further with only two trials.
Agreement or disagreements with other studies
or reviews
The result is consistent with other published reviews and with the
previous version of this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence in this area is sparse, of poor quality, and predates
the advances in reperfusion techniques and trial methods of recent
years. The evidence available is suggestive of harm but lacks power,
so this could be due to chance. Current evidence neither supports
nor clearly refutes the routine use of oxygen in people with AMI.
Implications for research
As long ago as 1950, it was demonstrated that the administration of
pure oxygen via a facial mask not only failed to reduce the duration
of angina pain but also prolonged the electrocardiographic changes
indicative of an AMI (Russek 1950). This ﬁnding was explicitly
identiﬁed as requiring further research over three decades ago (
Salzman 1975). Given that Rawles 1976 subsequently suggested
possible harm, it is surprising that a deﬁnitive study has not been
done to rule out the possibility that oxygen may do more harm
than good.
Part of the reason for the failure to fund such an essential studymay
be the strong a priori belief (Cabello 2009, Danchin 2009), based
on pathophysiological reasoning, that oxygen administrationmust
reduce both the oxygen deﬁcit in ischaemic myocardial tissue and
consequent tissue death. Indeed, both the medical profession and
the public are so familiar with the use of oxygen that the general
attitude may be that even if it is not doing any good it is not
going to be of any harm. However, in recent years oxygen has been
increasingly recognised as a “vasoactive substance”. In summary
,while there are pathophysiological reasons to believe that it may
have the potential to reduce tissue damage, it is also biologically
plausible that oxygen is doing harm (see above under ’Why it is
important to do this review’).
There are three registered ongoing trials and two of them are cur-
rently recruiting participants (NCT01272713; NCT01423929).
Both studies focus on the effect of oxygen on the infarct size esti-
mated by biochemical markers and magnetic resonance imaging
(MRI) (see Characteristics of ongoing studies) and focus on pa-
tients with STEMI. There are no ongoing trials seeking to address
as a primary outcome the question of whether routine use of oxy-
gen for AMI reduces pain or death.
Given the widespread use of oxygen for AMI, the inconsistencies
in recommendations about when and to whom it should be given,
and the fact that the best current evidence is suggestive of poten-
tial clinically signiﬁcant harm, we believe there is an urgent need
for an adequately powered randomised controlled trial to estab-
lish the effectiveness of, or harm from, the administration of oxy-
gen to people with AMI. That trial must incorporate contempo-
rary standards in design, conduct, analysis and reporting of trials
and address the spectrum, population and sample size mentioned
above to reﬂect contemporary diagnosis and care of the patient
with AMI.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by year of study]
Rawles 1976
Methods Double-blind, randomised controlled trial
Participants People with suspected AMI presenting within 24 hours after onset of symptoms. Sample
size 200
Interventions Oxygen or compressed air administered by MC mask at 6 L/min over 24 hours
Comparator: air at normal pressure given at 6 L/min by MC mask
Outcomes Death, arrhythmias, use of analgesics, maximum serum aspartate aminotransferase levels,
length of stay, systolic ejection time, hypoxaemia
Exclusions People with heart failure, bronchitis, emphysema, or other respiratory problems
Length of follow-up Discharge
Clinical Context and parallel care Prethrombolysis period
Notes Clinical setting: single site coronary care unit in the UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk There was no description of how the se-
quence was generated
Allocation concealment (selection bias) Low risk Numbered sealed envelopes
Blinding (performance bias and detection
bias)
Death
Low risk Double-blinded using shrouded cylinders
(but likely that the blinding could have
been compromised)
Blinding (performance bias and detection
bias)
Pain (or surrogate)
Unclear risk Double-blinded using shrouded cylinders
(but likely that the blinding could have
been compromised and this may affect the
assessment of this outcome: pain or suro-
gate)
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk Not applicable in this trial
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Rawles 1976 (Continued)
Incomplete outcome data (attrition bias)
Death
Low risk There were post-randomisation exclusions
due to unconﬁrmed AMI (19% air group
and 24% O group)
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
Infarct size (MRI)
Unclear risk Not applicable in this trial
Selective reporting (reporting bias) Low risk There was no protocol published but we
judged that there was no bias in reporting
the primary outcome
Other bias Low risk Other biases have been not identiﬁed
Baseline characteristics Low risk Consecutive participants, similar age, sex
Wilson 1997
Methods Randomised, open-label, controlled trial
Participants People with conﬁrmed AMI presenting within 24 hours of onset of symptoms. Sample
size 50
Interventions Oxygen by face mask at 4 L/min or normal air over 24 hours
Outcomes Hypoxaemia, arrhythmias, cardiac enzymes
Exclusions People with heart failure, cyanosis central or pulmonary disease requiring O
Length of follow-up Discharge
Clinical Context and parallel care Thrombolysis period
Notes Single-site coronary care unit in the UK. The primary purpose of this trial was to look
at the effect of oxygen on hypoxaemia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
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Wilson 1997 (Continued)
Allocation concealment (selection bias) Low risk Sealed envelopes for randomisation
Blinding (performance bias and detection
bias)
Death
Low risk This was an open-label trial (but the absence
of blinding is unlikely to introduce bias in
this outcome)
Blinding (performance bias and detection
bias)
Pain (or surrogate)
High risk This was an open-label trial, therefore the
risk of bias in this outcome cannot be ruled
out
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk Not relevant to this study
Incomplete outcome data (attrition bias)
Death
High risk Eight out of 50missingdata (groupnot spec-
iﬁed); one death, one stroke, four withdrew
consent, two with incomplete data
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
Unclear risk Not relevant in this study
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Not relevant in this study
Incomplete outcome data (attrition bias)
Infarct size (MRI)
Unclear risk Not relevant in this study
Selective reporting (reporting bias) High risk The main variables of the study were in-
cidence and degree of hypoxaemia and the
effect of oxygen administration. The main
outcome of this review (death) was not re-
ported, and in fact the only participant who
died was not included in the analysis
Other bias Low risk Other biases were not identiﬁed
Baseline characteristics Low risk Consecutive participants, similar age, smok-
ing and diabetes
Ukholkina 2005
Methods Randomised, open-label, controlled trial
Participants Conﬁrmed AMI within 12 hours of onset of symptoms. Sample size 137
Interventions Oxygen for three hours administered via nasal cannulae 3 - 6 L/min (FiO 30 - 40%)
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Ukholkina 2005 (Continued)
Outcomes Death, arrhythmias within one hour after reperfusion, surgery during hospital stay,
recurrent AMI, post-infarction angina, hypoxaemia, heart failure, pericarditis, area of
tissue damage measured by ECG mapping and cardiac enzymes
Exclusions People with complicated AMI, congestive heart failure, pulmonary disease, or anaemia
Length of follow-up 10 days
Clinical Context and parallel care Context of primary PCI
Notes Single-site coronary care unit in Russia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Death
Low risk This was an open-label trial (but absence of
blinding unlikely to introduces bias in this
outcome)
Blinding (performance bias and detection
bias)
Pain (or surrogate)
Unclear risk Not applicable in this trial (pain was not a
variable evaluated in the study)
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk This was an open-label trial (but the absence
of blinding unlikely to introduce bias in this
outcome)
Incomplete outcome data (attrition bias)
Death
High risk While mortality was adequately reported for
included participants, there was inadequate
description of exclusion post-randomisation
in each group (e.g. failed revascularisation)
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
High risk There was inadequate description of exclu-
sion post-randomisation in each group
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Inadequate description of exclusion post-
randomisation in each group (e.g. failed
revascularisation). Consequently, these par-
ticipants are not included in the infarct size
comparison. There were problems of consis-
tency in the measurement process of ECG
mapping done to estimate infarct size
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Ukholkina 2005 (Continued)
Incomplete outcome data (attrition bias)
Infarct size (MRI)
Unclear risk Not applicable in this trial
Selective reporting (reporting bias) High risk We have no information about the protocol,
but the infarct size estimation was only re-
ported in 31 patients in the oxygen group
and no information in the air group
Other bias High risk See baseline imbalances
Baseline characteristics High risk The groups were different at baseline in two
important variables:
1. Clinical class Killip and Kimball (Killip II
10% O versus 1% air group, P = 0.08)
2. Time to revascularisation 41 minutes
shorter in the air group
Ranchord 2012
Methods Open randomised controlled trial
Participants People with ischaemic symptoms + ST-segment elevation (0.1 mV) in two contiguous
leads STEMI or elevation (0.2 mV) in more of two precordial leads (STEMI), or with
ischaemic symptoms + new onset left bundle branch block. Sample size 148
Interventions Intervention: oxygen high ﬂow 6 L/mit by concentration mask
Comparator: oxygen titrated delivered by nasal prongs or mask adjusting the ﬂow-rate
to achieve an oxygen saturation of 93% - 96%
Outcomes 30 days mortality, complications, infarct size estimated by troponin T level measured 66
to 78 hours, infarct mass (absolute and as percentage) documented by MRI (measured
in 4 - 6 weeks after AMI only in a subset of participants), por-BNP measured 24 hours
after randomisation. As composite variable major cardiaca event (death, reinfarction,
target vessel revascularisation) at 30 days was used
Exclusions Previous myocardial infarction, chronic obstructive pulmonary disease (COPD), type
II respiratory failure, cardiogenic shock, oxygen desaturation below 85%; pregnancy,
bleomycin treatment or participation in another trial
Length of follow-up 30 days for mortality, Troponin T and BNP, 4 - 5 weeks after AMI for MRI
Clinical Context and parallel care The study was undertaken exclusively in-hospital patients therefore the pre-hospital
phase of AMI was not considered
Primary percutaneous coronary intervention (PPCI) was the ﬁrst-choice treatment in
one centre, while in the other PPCI or thrombolysis was the treatment, depending on
the hour of hospital admission
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Ranchord 2012 (Continued)
Notes The study was conducted in two centres.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sequence was undertaken by a computer pro-
gramme.
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding (performance bias and detection
bias)
Death
Low risk There is no threat for this outcome
Blinding (performance bias and detection
bias)
Pain (or surrogate)
Unclear risk Not applicable in this trial
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
Death
High risk There are 12 post-randomisation exclusions for
which there are no 30-day mortality data reported
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
High risk There are 12 post-randomisation exclusions in
which there are no reported biochemical data
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
Infarct size (MRI)
Unclear risk By deﬁnition, the primary outcome (30 days mor-
tality) implies thatMRIwas not performed (by pro-
tocol performed 4 - 5weeks after AMI). Data there-
fore not available
Selective reporting (reporting bias) High risk MRI was performed only in a subgroup of partici-
pants (selective reporting of subgroup)
Other bias High risk Prerandomisation oxygen was administered in ex-
perimental and control group (86.8% and 63%
respectively). This prerandomisation intervention
may have produced a bias in effect estimation to-
wards the null hypothesis
The comparison of infarct size measured by MRI
between the two groups should be considered a
non-randomised comparison therefore prone to the
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Ranchord 2012 (Continued)
bias of observational studies
Baseline characteristics Unclear risk There were differences in previous PCI, and in the
infarct territory: anterior infarction was less fre-
quent in the experimental group (18%) than in the
control group (31%)
ABBREVIATIONS:
STEMI = ST-segment elevation myocardial infarction
CHD = coronary heart disease
AMI = myocardial infarction
ACS = acute coronary syndrome
STEMI: ST-elevation acute myocardial infarction
SIGN = Scottish Intercollegiate Guidelines Network
RCT = randomised controlled trial
RR = risk ratio
ECG = electrocardiogram
LOE = level of evidence
MRI = magnetic resonance imaging
BNP = brain natriuretic peptide
SD = standard deviation
SE = standard error
ITT = intention-to-treat analysis
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AMIHOT 2003 Wrong intervention: aqueous oxygen therapy in STEMI
Dekleva 2004 Wrong intervention: hyperbaric oxygen versus air in participants after thrombolysis in AMI
Dotsenko 2007 Wrong intervention: hyperbaric oxygen versus air in conventionally treated participants with AMI
Haude 2007 Wrong intervention: supersaturated oxygen therapy after percutaneous coronary intervention in AMI
Kerr 1975 Different intervention: nitrous oxide 50% with or without oxygen 50% versus air in participants with AMI
Shandling 1997 Wrong intervention: hyperbaric oxygen
Slagboom 2005 Wrong intervention: haemoglobin-based oxygen therapeutics in elective PCI
AMI = acute myocardial infarction
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PCI = percutaneous coronary intervention
STEMI = ST-segment elevation myocardial infarction
Characteristics of ongoing studies [ordered by study ID]
ACTRN12609000466246
Trial name or title A randomised controlled trial comparing controlled oxygen therapy versus high ﬂow oxygen therapy for acute
myocardial infarctions in the prehospital setting (no speciﬁc name available)
Methods Randomised controlled trial, parallel design with open label and allocation concealment
Participants People with chest pain and suspicion of acute coronary syndrome attended by Tasmanian ambulance service
in the Launceston region
Interventions High ﬂow oxygen 8 - 15 L/min by non-breather mask compared to oxygen therapy to maintain oxygen
saturation between 92% - 96%
Outcomes Primary outcome: Mortality during ambulance or in the hospital stay. Secondary outcomes:
1.Time to resolution of chest pain using a 0 - 10 scale and an electronic system for reporting data
2. Length of hospital stay
Starting date Theoretically January 2012
Contact information Dr Michael Austin, Menzies Research Institute (Private Bag 23) Hobart TAS 7001. maaustin@utas.edu.au
Notes Not recruiting yet (register visited last time January 1st 2013)
NCT01272713
Trial name or title Air Versus Oxygen in myocarDial infarction study (AVOID)
Methods Multicentric open-label randomised controlled trial
Participants Participants uncomplicated acute ST-elevationmyocardial infarction (STEMI) or ischaemic pain + left bundle
branch block
Interventions Oxygen by mask 8 L/min versus air. If the oxygen saturation falls below 94% then titrated oxygen was
administered to achieve an oxygen saturation of 94%
Outcomes Infarct size evaluated by cTnl and CK (peak and area under curve) at 72 hours of reperfusion. Survival to
hospital discharge, Infarct size on MRI (in a subset of participants), Major adverse cardiac events (MACE) at
six months
Starting date Octorer 2011
Contact information Dion Stub. d.stub@alfred.org.au
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NCT01272713 (Continued)
Notes The protocol and a feasibility study have been published (see studies awaiting for classiﬁcation)
NCT01423929
Trial name or title Suplemental Oxygen in Catheterization Coronary Emergency Reperfusion (SOCCER)
Methods Multicentre single-blind randomised controlled trial
Participants Normoxic STEMI ambulance patients with symptom duration less than six hours
Interventions Oxygen 10 L/min by oxymask™ versus room air
Outcomes Infarct size estimated by MRI at day four, myocardial salvage index by MRI, echocardiography (acute and six
months after AMI), pro-BNP, dose of opioids
Starting date January 2012
Contact information Mahin Akbarzadeh (Skåne University Hospital at Lund)
Notes Three hospitals with PPCI capabilities.
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D A T A A N D A N A L Y S E S
Comparison 1. Oxygen versus air
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death in hospital for participants
with acute MI
3 430 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [0.78, 5.68]
2 Death in hospital for participants
with acute MI (random-effects)
3 430 Risk Ratio (M-H, Random, 95% CI) 2.12 [0.74, 6.10]
3 Death in hospital for all
participants (including those
who did not have an AMI)
3 485 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [0.75, 5.58]
4 Death in hospital for all
participants (including
those who did not have an
AMI)(random-effects)
3 485 Risk Ratio (M-H, Random, 95% CI) 2.05 [0.71, 5.92]
5 Opiate use (as a proxy measure
for pain) for participants with
an AMI
2 199 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.83, 1.18]
6 Opiate use (as a proxy measure
for pain) for participants with
an AMI (random-effects)
2 199 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.72, 1.23]
7 Opiate use (as a proxy measure
for pain) for all participants on
ITT (including those who did
not have an AMI)
2 250 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.78, 1.20]
8 Opiate use (as a proxy measure
for pain) for all participants
on ITT (including those
who did not have an AMI)
(random-effects
2 250 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.78, 1.38]
9 Complications of AMI 1 137 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.45, 1.03]
10 Death in hospital for all
participants (including those
who did not have an AMI) trials
done in the revascularization
era
2 285 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.21, 6.32]
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Analysis 1.1. Comparison 1 Oxygen versus air, Outcome 1 Death in hospital for participants with acute MI.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 1 Death in hospital for participants with acute MI
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 9/80 3/77 55.8 % 2.89 [ 0.81, 10.27 ]
Ukholkina 2005 1/58 0/79 7.7 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/68 2/68 36.5 % 0.50 [ 0.05, 5.39 ]
Total (95% CI) 206 224 100.0 % 2.11 [ 0.78, 5.68 ]
Total events: 11 (Experimental), 5 (Control)
Heterogeneity: Chi2 = 1.81, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.2. Comparison 1 Oxygen versus air, Outcome 2 Death in hospital for participants with acute MI
(random-effects).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 2 Death in hospital for participants with acute MI (random-effects)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rawles 1976 9/80 3/77 69.3 % 2.89 [ 0.81, 10.27 ]
Ukholkina 2005 1/58 0/79 11.0 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/68 2/68 19.7 % 0.50 [ 0.05, 5.39 ]
Total (95% CI) 206 224 100.0 % 2.12 [ 0.74, 6.10 ]
Total events: 11 (Experimental), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.81, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.3. Comparison 1 Oxygen versus air, Outcome 3 Death in hospital for all participants (including
those who did not have an AMI).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 3 Death in hospital for all participants (including those who did not have an AMI)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 9/105 3/95 57.1 % 2.71 [ 0.76, 9.73 ]
Ukholkina 2005 1/58 0/79 7.7 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 2/76 35.3 % 0.53 [ 0.05, 5.70 ]
Total (95% CI) 235 250 100.0 % 2.05 [ 0.75, 5.58 ]
Total events: 11 (Experimental), 5 (Control)
Heterogeneity: Chi2 = 1.61, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.4. Comparison 1 Oxygen versus air, Outcome 4 Death in hospital for all participants (including
those who did not have an AMI)(random-effects).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 4 Death in hospital for all participants (including those who did not have an AMI)(random-effects)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rawles 1976 9/105 3/95 69.0 % 2.71 [ 0.76, 9.73 ]
Ukholkina 2005 1/58 0/79 11.1 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 2/76 19.9 % 0.53 [ 0.05, 5.70 ]
Total (95% CI) 235 250 100.0 % 2.05 [ 0.71, 5.92 ]
Total events: 11 (Experimental), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.61, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.5. Comparison 1 Oxygen versus air, Outcome 5 Opiate use (as a proxy measure for pain) for
participants with an AMI.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 5 Opiate use (as a proxy measure for pain) for participants with an AMI
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1997 16/22 18/20 26.2 % 0.81 [ 0.60, 1.08 ]
Rawles 1976 57/80 52/77 73.8 % 1.06 [ 0.86, 1.30 ]
Total (95% CI) 102 97 100.0 % 0.99 [ 0.83, 1.18 ]
Total events: 73 (Experimental), 70 (Control)
Heterogeneity: Chi2 = 2.18, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.6. Comparison 1 Oxygen versus air, Outcome 6 Opiate use (as a proxy measure for pain) for
participants with an AMI (random-effects).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 6 Opiate use (as a proxy measure for pain) for participants with an AMI (random-effects)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rawles 1976 57/80 52/77 57.6 % 1.06 [ 0.86, 1.30 ]
Wilson 1997 16/22 18/20 42.4 % 0.81 [ 0.60, 1.08 ]
Total (95% CI) 102 97 100.0 % 0.94 [ 0.72, 1.23 ]
Total events: 73 (Experimental), 70 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.18, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.7. Comparison 1 Oxygen versus air, Outcome 7 Opiate use (as a proxy measure for pain) for all
participants on ITT (including those who did not have an AMI).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 7 Opiate use (as a proxy measure for pain) for all participants on ITT (including those who did not have an AMI)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 57/105 52/95 75.2 % 0.99 [ 0.77, 1.28 ]
Wilson 1997 16/25 18/25 24.8 % 0.89 [ 0.61, 1.30 ]
Total (95% CI) 130 120 100.0 % 0.97 [ 0.78, 1.20 ]
Total events: 73 (Experimental), 70 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.8. Comparison 1 Oxygen versus air, Outcome 8 Opiate use (as a proxy measure for pain) for all
participants on ITT (including those who did not have an AMI) (random-effects.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 8 Opiate use (as a proxy measure for pain) for all participants on ITT (including those who did not have an AMI) (random-effects
Study or subgroup Experimental Control
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rawles 1976 57/105 52/95 87.9 % 1.01 [ 0.75, 1.37 ]
Wilson 1997 16/25 18/25 12.1 % 1.29 [ 0.57, 2.91 ]
Total (95% CI) 130 120 100.0 % 1.04 [ 0.78, 1.38 ]
Total events: 73 (Experimental), 70 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
Analysis 1.9. Comparison 1 Oxygen versus air, Outcome 9 Complications of AMI.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 9 Complications of AMI
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ukholkina 2005 20/58 40/79 100.0 % 0.68 [ 0.45, 1.03 ]
Total (95% CI) 58 79 100.0 % 0.68 [ 0.45, 1.03 ]
Total events: 20 (Experimental), 40 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.10. Comparison 1 Oxygen versus air, Outcome 10 Death in hospital for all participants (including
those who did not have an AMI) trials done in the revascularization era.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 10 Death in hospital for all participants (including those who did not have an AMI) trials done in the revascularization era
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ukholkina 2005 1/58 0/79 17.9 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 2/76 82.1 % 0.53 [ 0.05, 5.70 ]
Total (95% CI) 130 155 100.0 % 1.16 [ 0.21, 6.32 ]
Total events: 2 (Experimental), 2 (Control)
Heterogeneity: Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oxygen Favours air
A P P E N D I C E S
Appendix 1. Search strategies 2010
CENTRAL on The Cochrane Library
#1 MeSH descriptor Myocardial Infarction explode all trees
#2 myocardial next infarct*
#3 heart next infarct*
#4 (acute near/3 coronary )
#5 (coronary near/3 syndrome* )
#6 heart next attack*
#7 MeSH descriptor Coronary Thrombosis this term only
#8 coronary near/3 thrombosis
#9 ami
#10 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
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#11 MeSH descriptor Oxygen Inhalation Therapy explode all trees
#12 oxygen
#13 (#10 and #12)
MEDLINE on Ovid
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.13 oxygen.ti. or Oxygenotherapy/
14 or/11-13
15 10 and 14
16 randomized controlled trial.pt.
17 controlled clinical trial.pt.
18 randomized controlled trials.sh.
19 random allocation.sh.
20 double blind method.sh.
21 single-blind method.sh.
22 or/16-21
23 (animals not humans).sh.
24 22 not 23
25 clinical trial.pt.
26 exp clinical trials/
27 (clin$ adj25 trial$).ti,ab.
28 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
29 placebos.sh.
30 placebo$.ti,ab.
31 random$.ti,ab.
32 research design.sh.
33 or/25-32
34 33 not 23
35 34 not 24
36 comparative study.sh.
37 exp evaluation studies/
38 follow up studies.sh.
39 prospective studies.sh.
40 (control$ or prospectiv$ or volunteer$).ti,ab.
41 or/36-40
42 41 not 23
43 42 not (24 or 35)
44 24 or 35 or 43
45 15 and 44
EMBASE on Ovid
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1 exp Heart Infarction/
2 Coronary Artery Thrombosis/
3 myocardial infarct$.tw.
4 heart attack$.tw.
5 heart infarct$.tw.
6 (coronary adj3 syndrome$).tw.
7 acute coronary.tw.
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 oxygen therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti.
14 or/11-13
15 10 and 14
Pascal
1 oxygen.mp. [mp=abstract, descriptors - english, descriptors - french, descriptors - spanish, heading words, identiﬁers - english,
identiﬁers - french, identiﬁers - spanish, title, translated title]
2 myocardial infarction.mp. [mp=abstract, descriptors - english, descriptors - french, descriptors - spanish, heading words, identiﬁers -
english, identiﬁers - french, identiﬁers - spanish, title, translated title]
3 acute coronary syndrome.mp. [mp=abstract, descriptors - english, descriptors - french, descriptors - spanish, heading words, identiﬁers
- english, identiﬁers - french, identiﬁers - spanish, title, translated title]
4 2 or 3
5 1 and 4
6 random$.mp. [mp=abstract, descriptors - english, descriptors - french, descriptors - spanish, heading words, identiﬁers - english,
identiﬁers - french, identiﬁers - spanish, title, translated title]
7 5 and 6
CINAHL (EBSCO)
(heart attack* or MI or AMI or heart infarct* or myocardial infarct* or coronary syndrome or coronary thrombosis) AND ((oxygen)
AND (random* or control* or trial*)
LILACS (BIREME)
(heart or MI or AMI or myocardial or coronary) AND (oxygen) AND (random* or control* or trial*)
ISI Proceedings (Web of Knowledge)
(heart or MI or AMI or myocardial or coronary) AND (oxygen) AND (random* or control* or trial*)
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Appendix 2. Search strategies 2012
CENTRAL
#1(preoperative physical therapy):ti
#2MeSH descriptor Myocardial Infarction explode all trees
#3(myocardial infarct*)
#4(heart attack*)
#5(heart infarct*)
#6(coronary near/3 syndrome*)
#7”acute coronary“
#8MeSH descriptor Coronary Thrombosis, this term only
#9 ”coronary thrombosis“
#10(ami)
#11(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12MeSH descriptor Oxygen Inhalation Therapy, this term only
#13(oxygen near/3 (therapy or treat* or effect* or admin* or inhal*))
#14(oxygen):ti
#15(oxygenotherapy)
#16(#12 OR #13 OR #14 OR #15)
#17(#11 AND #16), from 2010 to 2012
MEDLINE (OVID)
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti. or Oxygenotherapy.tw.
14 or/11-13
15 10 and 14
16 randomized controlled trial.pt.
17 controlled clinical trial.pt.
18 randomized.ab.
19 placebo.ab.
20 drug therapy.fs.
21 randomly.ab.
22 trial.ab.
23 groups.ab.
24 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 exp animals/ not humans.sh.
26 24 not 25
27 15 and 26
28 limit 27 to yr=”2010 -Current“
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EMBASE (OVID)
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti. or Oxygenotherapy.tw.
14 or/11-13
15 10 and 14
16 random$.tw.
17 factorial$.tw.
18 crossover$.tw.
19 cross over$.tw.
20 cross-over$.tw.
21 placebo$.tw.
22 (doubl$ adj blind$).tw.
23 (singl$ adj blind$).tw.
24 assign$.tw.
25 allocat$.tw.
26 volunteer$.tw.
27 crossover procedure/
28 double blind procedure/
29 randomized controlled trial/
30 single blind procedure/
31 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 (animal/ or nonhuman/) not human/
33 31 not 32
34 15 and 33
35 limit 34 to yr=”2010 -Current“
CINAHL
S19 S14 and S17 Limiters - Published Date from: 20100101-20120731
S18 S14 and S17
S17 S15 or S16
S16 (MH ”Randomized Controlled Trials“)
S15 random* or blind* or allocat* or trial* or placebo* or crossover* or cross-over*
S14 S10 and S13
S13 S11 or S12
S12 oxygen or oxygenotherapy
S11 (MH ”Oxygen Therapy+“)
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9
S9 ami
S8 coronary N3 thrombosis
S7 (MH ”Coronary Thrombosis“)
S6 (heart attack*)
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S5 (coronary N3 syndrome* )
S4 (acute N3 coronary )
S3 (heart infarct*)
S2 (myocardial infarct*)
S1 (MH ”Myocardial Infarction+“)
Web of Science
#14 #13 AND #12 AND #8
#13 Topic=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))
#12 #11 OR #10 OR #9
#11 Topic=(oxygenotherapy)
#10 Title=((oxygen near/3 (therapy or treat* or effect* or admin* or inhal*)))
#9 Title=(oxygen)
#8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#7 Topic=(ami)
#6 Topic=(coronary near/3 thrombosis)
#5 Topic=((heart attack*))
#4 Topic=((coronary near/3 syndrome* ))
#3 Topic=((acute near/3 coronary ))
#2 Topic=((heart infarct*))
#1 Topic=((myocardial infarct*))
WH A T ’ S N E W
Last assessed as up-to-date: 17 July 2012.
Date Event Description
7 April 2013 New search has been performed The updated search was conducted in May 2013, and
identiﬁed one new trial for inclusion and three ongoing
trials
7 April 2013 New citation required but conclusions have not changed One new study included
C O N T R I B U T I O N S O F A U T H O R S
Juan Cabello provided expert advice, co-wrote the protocol and helped with quality assessment, data extraction, writing the discussion
and entering data into RevMan.
Amanda Burls co-wrote the protocol, contacted authors for further information and contributed to quality assessment, data extraction,
analysis, writing the discussion, and entering data into Review Manager 5.
Sue Bayliss undertook the electronic searches, helped obtain papers and proofread the review.
Jose Emparanza Knorr co-wrote the protocol and contributed to quality assessment, data extraction, analysis and writing the discussion.
TomQuinn provided expert advice, contacted experts to ﬁnd unpublished studies and contributed to quality assessment, data extraction
and writing the discussion.
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D E C L A R A T I O N S O F I N T E R E S T
None on starting this review. After starting this systematic review some of the authors have put together, with other clinical colleagues,
a proposal for a randomised controlled trial in the UK of oxygen for AMI in the pre-hospital setting.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• None, Not speciﬁed.
No ﬁnancial support was received for this review
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Data were too sparse to permit adequate analysis of the subgroups that had been prespeciﬁed for exploration.
We made two changes:
1. One minor change in the search strategy to improve the sensitivity, i.e. the inclusion of the text word ’oxygenotherapy’ in the title
(the original search failed to pick up the Russian article and we looked to see if it was in MEDLINE and, if so, why the search strategy
had missed it);
2. After the protocol was published, a new version of the Cochrane Handbook recommended a new approach to assessment of risk of
bias, so we changed our method of assessment to be consistent with the recommendations.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Oxygen Inhalation Therapy [adverse effects; mortality]; Air; Analgesics [therapeutic use]; Myocardial Infarction [mortality; ∗therapy];
Randomized Controlled Trials as Topic
MeSH check words
Humans
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